However, HER2+/ER+ breast cancer is primarily treated with HER2-targeted therapies, even though the complex crosstalk and reciprocal signalling between the HER2 and ER pathways can lead to the development of resistance when HER2 or ER therapies are used as single agents [4,5]. This evidence concerns the gene ESR1 and breast cancer.